Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.

Velizheva NP, Rechsteiner MP, Valtcheva N, Freiberger SN, Wong CE, Vrugt B, Zhong Q, Wagner U, Moch H, Hillinger S, Schmitt-Opitz I, Soltermann A, Wild PJ, Tischler V.

Pathol Res Pract. 2018 Apr;214(4):572-578. doi: 10.1016/j.prp.2018.02.001. Epub 2018 Feb 16.


Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.

Velizheva NP, Rechsteiner MP, Wong CE, Zhong Q, Rössle M, Bode B, Moch H, Soltermann A, Wild PJ, Tischler V.

Cancer Cytopathol. 2017 Jan;125(1):30-40. doi: 10.1002/cncy.21771. Epub 2016 Sep 16.


Automated assessment of β-cell area and density per islet and patient using TMEM27 and BACE2 immunofluorescence staining in human pancreatic β-cells.

Rechsteiner MP, Floros X, Boehm BO, Marselli L, Marchetti P, Stoffel M, Moch H, Spinas GA.

PLoS One. 2014 Jun 6;9(6):e98932. doi: 10.1371/journal.pone.0098932. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e109467.


Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.

Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP.

Virchows Arch. 2013 Nov;463(5):623-31. doi: 10.1007/s00428-013-1492-3. Epub 2013 Oct 2.


Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.

Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M.

Cancer Cytopathol. 2014 Jan;122(1):48-58. doi: 10.1002/cncy.21352. Epub 2013 Sep 4.


Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass.

Esterházy D, Stützer I, Wang H, Rechsteiner MP, Beauchamp J, Döbeli H, Hilpert H, Matile H, Prummer M, Schmidt A, Lieske N, Boehm B, Marselli L, Bosco D, Kerr-Conte J, Aebersold R, Spinas GA, Moch H, Migliorini C, Stoffel M.

Cell Metab. 2011 Sep 7;14(3):365-77. doi: 10.1016/j.cmet.2011.06.018.


VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.

Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H.

Cancer Res. 2011 Aug 15;71(16):5500-11. doi: 10.1158/0008-5472.CAN-11-0757. Epub 2011 Jun 29.


TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification.

Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M, Berger C, Bernasconi M, Schaefer BW, Speck RF, Nadal D.

Oncogene. 2010 Aug 12;29(32):4588-98. doi: 10.1038/onc.2010.203. Epub 2010 May 31.


Graph-based pancreatic islet segmentation for early type 2 diabetes mellitus on histopathological tissue.

Floros X, Fuchs TJ, Rechsteiner MP, Spinas G, Moch H, Buhmann JM.

Med Image Comput Comput Assist Interv. 2009;12(Pt 2):633-40.


Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.

Rechsteiner MP, Bernasconi M, Berger C, Nadal D.

Trends Microbiol. 2008 Nov;16(11):520-7. doi: 10.1016/j.tim.2008.08.007. Epub 2008 Oct 3.


Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection.

Rechsteiner MP, Berger C, Zauner L, Sigrist JA, Weber M, Longnecker R, Bernasconi M, Nadal D.

J Virol. 2008 Feb;82(4):1739-47. Epub 2007 Dec 5.


Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells.

Rechsteiner MP, Berger C, Weber M, Sigrist JA, Nadal D, Bernasconi M.

J Gen Virol. 2007 May;88(Pt 5):1454-9.


Ligand binding properties of bacterial hemoglobins and flavohemoglobins.

Farrés J, Rechsteiner MP, Herold S, Frey AD, Kallio PT.

Biochemistry. 2005 Mar 15;44(10):4125-34.


Supplemental Content

Loading ...
Support Center